Feedback
Settings

Settings

Goto Application

1. WO2020223646 - METHODS FOR CANCER DETECTION BY EVALUATION OF ALPHA-1-ANTITRYPSIN (AAT) AND CHYMOTRYPSIN-LIKE ELASTASE IN GASTROINTESTINAL LAVAGE FLUID SAMPLES

PermaLink
Publication Number WO/2020/223646
Publication Date 05.11.2020
International Application No. PCT/US2020/031062
International Filing Date 01.05.2020
IPC
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G01N 33/68 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61K 31/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
CPC
G01N 2333/8125
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
81Protease inhibitors
8107Endopeptidase (E.C. 3.4.21-99) inhibitors
811Serine protease (E.C. 3.4.21) inhibitors
8121Serpins
8125Alpha-1-antitrypsin
G01N 2333/96411
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
90Enzymes; Proenzymes
914Hydrolases (3)
948acting on peptide bonds (3.4)
95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
964derived from animal tissue
96402from non-mammals
96405in general
96408with EC number
96411Serine endopeptidases (3.4.21)
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 2800/60
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
60Complex ways of combining multiple protein biomarkers for diagnosis
G01N 33/57438
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57438of liver, pancreas or kidney
G01N 33/6848
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6803General methods of protein analysis not limited to specific proteins or families of proteins
6848Methods of protein analysis involving mass spectrometry
Applicants
  • CREATICS LLC [US]/[US]
Inventors
  • PANNELL, Lewis, K.
Agents
  • ZACHARAKIS, Maria, Laccotripe
  • BENNETT, Coalton
  • BAI, Mei
  • BAJAJ, Shama
  • BLAZESKI, George
Priority Data
62/842,13502.05.2019US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR CANCER DETECTION BY EVALUATION OF ALPHA-1-ANTITRYPSIN (AAT) AND CHYMOTRYPSIN-LIKE ELASTASE IN GASTROINTESTINAL LAVAGE FLUID SAMPLES
(FR) MÉTHODES DE DÉTECTION DU CANCER PAR ÉVALUATION DE ALPHA-1-ANTITRYPSINE (AAT) ET ELASTASE DE TYPE CHYMOTRYPSINE DANS DES ÉCHANTILLONS DE FLUIDE DE LAVAGE GASTRO-INTESTINAL
Abstract
(EN) Described herein are methods for detection of pancreatic cancer that are highly sensitive, highly specific and also non-invasive. Samples comprising gastrointestinal lavage fluid (GLF) are obtained from subjects, and the levels of two specific polypeptide or peptide fragments thereof in the GLF, namely the alpha- 1 -antitrypsin (AAT) and a chymotrypsin-like elastase, e.g., chymotrypsin-like elastase family member 2A (CLE2A), are detected and measured. The level of AAT or a peptide fragment thereof increases in a pancreatic cancer patient while the level of the chymotrypsin-like elastase, e.g., CLE2A, or a peptide fragment thereof decreases.
(FR) L'invention concerne des procédés de détection du cancer du pancréas qui sont hautement sensibles, hautement spécifiques et également non invasifs. Des échantillons comprenant un fluide de lavage gastro-intestinal (GLF) sont obtenus à partir de sujets, et les taux de deux polypeptides ou fragments peptidiques spécifiques de celui-ci dans le GLF, à savoir l'alpha-1-antitrypsine (AAT) et une élastase de type chymotrypsine, par exemple, un élément 2A (CLE2A) de la famille de l'élastase de type chymotrypsine, sont détectés et mesurés. Le niveau d'AAT ou d'un fragment peptidique de celui-ci augmente chez un patient atteint d'un cancer du pancréas tandis que le niveau de l'élastase de type chymotrypsine, par exemple CLE2A, ou un fragment peptidique de celui-ci, diminue.
Latest bibliographic data on file with the International Bureau
# -